Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 May 3;76(9):1646-1654.
doi: 10.1093/cid/ciad020.

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

Edgar T Overton  1 , Gary Richmond  2 , Giuliano Rizzardini  3   4 , Anders Thalme  5 , Pierre-Marie Girard  6 , Alexander Wong  7 , Norma Porteiro  8 , Susan Swindells  9 , Jacques Reynes  10   11 , Sebastian Noe  12 , Conn Harrington  13 , Carlos Martín Español  14 , Carolina Acuipil  15 , Asma Aksar  16 , Yuanyuan Wang  17 , Susan L Ford  18 , Herta Crauwels  19 , Veerle van Eygen  20 , Rodica Van Solingen-Ristea  21 , Christine L Latham  22 , Shanker Thiagarajah  23 , Ronald D'Amico  15 , Kimberly Y Smith  15 , Kati Vandermeulen  24 , William R Spreen  15
Affiliations
Clinical Trial

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

Edgar T Overton et al. Clin Infect Dis. .

Abstract

Background: Cabotegravir (CAB) + rilpivirine (RPV) dosed intramuscularly monthly or every 2 months is a complete, long-acting (LA) regimen for the maintenance of HIV-1 virologic suppression. Here, we report the antiretroviral therapy as long acting suppression (ATLAS)-2M study week 152 results.

Methods: ATLAS-2M is a phase 3b, randomized, multicenter study assessing the efficacy and safety of CAB+RPV LA every 8 weeks (Q8W) versus every 4 weeks (Q4W). Virologically suppressed (HIV-1 RNA <50 copies/mL) individuals were randomized to receive CAB+RPV LA Q8W or Q4W. Endpoints included the proportion of participants with plasma HIV-1 RNA ≥50 copies/mL and <50 copies/mL, incidence of confirmed virologic failure (CVF; 2 consecutive measurements ≥200 copies/mL), safety, and tolerability.

Results: A total of 1045 participants received CAB+RPV LA (Q8W, n = 522; Q4W, n = 523). CAB+RPV LA Q8W demonstrated noninferior efficacy versus Q4W dosing, with 2.7% (n = 14) and 1.0% (n = 5) of participants having HIV-1 RNA ≥50 copies/mL, respectively, with adjusted treatment difference being 1.7% (95% CI: 0.1-3.3%), meeting the 4% noninferiority threshold. At week 152, 87% of participants maintained HIV-1 RNA <50 copies/mL (Q8W, 87% [n = 456]; Q4W, 86% [n = 449]). Overall, 12 (2.3%) participants in the Q8W arm and 2 (0.4%) in the Q4W arm had CVF. Eight and 10 participants with CVF had treatment-emergent, resistance-associated mutations to RPV and integrase inhibitors, respectively. Safety profiles were comparable, with no new safety signals observed since week 48.

Conclusions: These data demonstrate virologic suppression durability with CAB+RPV LA Q8W or Q4W for ∼3 years and confirm long-term efficacy, safety, and tolerability of CAB+RPV LA as a complete regimen to maintain HIV-1 virologic suppression.

Keywords: HIV-1; antiretroviral therapy; cabotegravir; long-acting; rilpivirine.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. E. T. O. has received research support to their institution during the conduct of this study and has served as a consultant for Merck and ViiV Healthcare, outside of the submitted work. E. T. O. joined ViiV Healthcare after the conclusion of the week 152 analysis. G. Richmond received grants for clinical trials from Gilead, TaiMed, Insmed, and ViiV Healthcare, outside the submitted work. G. Rizzardini has received payment/honoraria from Gilead, GSK, MSD, and ViiV Healthcare, outside of the submitted work, and reports participation on a Data Safety Monitoring Board or Advisory Board for ViiV, GSK, and Gilead. A. T. has served as a consultant on advisory boards for GSK and received payment for presentations by GSK and ViiV Healthcare (Nordic countries), outside of the submitted work. S. N. reports consulting fees and payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or education events from Gilead Sciences, MSD, Janssen, and ViiV Healthcare and support for attending meetings and/or travel from Gilead Sciences, Janssen, and ViiV Healthcare. N. P. reports payment of honoraria for educational events not related to this manuscript. A. W. reports grants and personal fees and honoraria for lectures and presentations from Gilead, Merck, and ViiV Healthcare, outside the submitted work. S. S. reports payments to their institution for clinical trial participation for the submitted work from ViiV Healthcare, salary support for research from the National Institutes of Health (NIH), and participation on a Data and Safety Monitoring Board for NIH. J. R. reports personal fees from Gilead (consulting and payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events), Janssen (payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events), Merck (payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events), Theratechnologies (payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events), and ViiV Healthcare (consulting and payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events) and support for attending meetings and/or travel from Gilead and Pfizer, outside of the submitted work. C. H., C. L., R. D., K. Y. S., C. A., and W. R. S. are employees of ViiV Healthcare and stockholders of GSK. K. Y. S. also reports a role as ViiV Employee-Head of Research and Development and as a member of the ViiV Leadership Team. C. M. E., A. A., Y. W., S. L. F., and S. T. are employees and stockholders of GSK. S. L. F. also reports that GSK provides support for travel and registration to conferences as relevant and a patent application with GSK (author is named as an inventor on the patent application for a Method of Treating HIV with Cabotegravir and Rilpivirine). S. T. also reports stocks in Haleon. H. C., V. v. E., R. V. S.-R., and K. V. are employees and stockholders of Janssen, Pharmaceutical Companies of Johnson & Johnson. V. v. E. also reports the following: the US application or Patent Cooperation Treaty international application number 62/870,413 filed on 3 July 2019 (TIP1068USPSP1 Methods of Treating HIV. The disclosure is directed to the use of rilpivirine, or a salt thereof, to treat HIV infections in pediatric subjects). All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Participant disposition. No study withdrawals were due to COVID-19 adverse events; however, 2 participants withdrew for COVID-19–related reasons (travel restrictions, n = 1; participant did not want to return to the clinic due to the pandemic, n = 1). aA total of 1049 participants were randomized. However, 4 participants did not receive the study drug and therefore were not part of the ITT-E population. bSeven participants completed the maintenance phase but did not enter the extension phase (Q8W, n = 5; Q4W, n = 2). Abbreviations: CAB, cabotegravir; COVID-19, coronavirus disease 2019; ITT-E, intention-to-treat exposed; LA, long-acting; Q4W, every 4 weeks; Q8W, every 8 weeks; RPV, rilpivirine.
Figure 2.
Figure 2.
ISRs over time. aAE grade is the maximum grade reported by the participant at each visit. bThere were no grade 4 or 5 ISRs. Abbreviations: AE, adverse event; CAB, cabotegravir; ISR, injection-site reaction; LA, long-acting; NA, not applicable; Q4W, every 4 weeks; Q8W, every 8 weeks; RPV, rilpivirine.
See this image and copyright information in PMC

Comment in

References

    1. Lesko CR, Cole SR, Hall HI, et al. . The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009-11. Int J Epidemiol 2016; 45:140–50. - PMC - PubMed
    1. Murphy EL, Collier AC, Kalish LA, et al. . Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135:17–26. - PubMed
    1. US Department of Health and Human Services . Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available at:https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult.... Accessed 1 September 2022.
    1. Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence 2019; 13:475–90. - PMC - PubMed
    1. De Los Rios P, Young B, Marcotullio S, et al. . 1329. Experiences and emotional challenges of antiretroviral treatment (ART)—findings from the positive perspectives study. Open Forum Infect Dis 2019; 6(Suppl 2):S481.

Publication types